chartexchange

Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire Inc. | Nov 16, 2026 8:00 AM EST

IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration

Read original article